BioWorld Asia

April 24, 2002

Xenova Enters Potential $63M Deal With Genentech For OX40

LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International) Read More

Finnish Companies Biotie, Contral, Carbion Plan Three-Way Merger

Leukemia Case Report Gives Gene Therapy Projects Pause For Thought

Apovia Raises EUR19M Privately To Fund Vaccine Development

YM BioSciences Plans Floats On AIM, TSE To Raise Up To C$40M

Faust Pharmaceuticals Obtains $2.6M To Develop CNS Drugs

Report Says EU Biotech Trails U.S. Due To Lack Of Coordination

Molecular Skincare Spun Out To Develop Skin Disease Treatments

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...